High burden of RSV hospitalization in very young children: a data linkage study

N. HOMAIRA1*, J.-L. OEI1,2, K-A. MALLITT1, M. E. ABDEL-LATIF3, L. HILDER4, B. BAJUK5, K. LUI1, M. FERSON6,7, A. NURKIC6, G. M. CHAMBERS4, W. RAWLINSON8,9,10, T. SNELLING11,12,13 AND A. JAFFE1,14

1 Discipline of Paediatrics, School of Women’s and Children’s Health, Faculty of Medicine, UNSW Australia; 2 Department of Neonatal Care, Royal Hospital for Women, Randwick, Sydney, Australia; 3 Department of Neonatology, Centenary Hospital, Australian National University; 4 National Perinatal Epidemiology & Statistics Unit, Centre for Big Data Research in Health and School of Women’s and Children’s Health, UNSW Australia; 5 NSW Pregnancy and Newborn Services Network, Sydney Children’s Hospitals Network, Westmead, NSW, Australia; 6 Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia; 7 School of Public Health & Community Medicine, Faculty of Medicine, UNSW Australia; 8 Serology and Virology Division, SEALS Microbiology, Prince of Wales Hospital, Randwick, NSW, Australia; 9 School of Medical Sciences, UNSW Australia; 10 School of Biotechnology and Biomolecular Sciences, UNSW Australia; 11 Princess Margaret Hospital, Perth, Western Australia; 12 Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, University of Western Australia; 13 Menzies School of Health Research and Charles Darwin University, Darwin; 14 Respiratory Department, Sydney Children’s Hospital, Randwick, Sydney, Australia

Received 28 July 2015; Final revision 28 October 2015; Accepted 4 November 2015; first published online 2 December 2015

SUMMARY

Linked administrative population data were used to estimate the burden of childhood respiratory syncytial virus (RSV) hospitalization in an Australian cohort aged <5 years. RSV-coded hospitalizations data were extracted for all children aged <5 years born in New South Wales (NSW), Australia between 2001 and 2010. Incidence was calculated as the total number of new episodes of RSV hospitalization divided by the child-years at risk. Mean cost per episode of RSV hospitalization was estimated using public hospital cost weights. The cohort comprised of 870 314 children. The population-based incidence/1000 child-years of RSV hospitalization for children aged <5 years was 4·9 with a rate of 25·6 in children aged <3 months. The incidence of RSV hospitalization (per 1000 child-years) was 11·0 for Indigenous children, 81·5 for children with bronchopulmonary dysplasia (BPD), 10·2 for preterm children with gestational age (GA) 32–36 weeks, 27·0 for children with GA 28–31 weeks, 39·0 for children with GA <28 weeks and 6·7 for term children with low birthweight. RSV hospitalization was associated with an average annual cost of more than AUD 9 million in NSW. RSV was associated with a substantial burden of childhood hospitalization specifically in children aged <3 months and in Indigenous children and children born preterm or with BPD.

Key words: Epidemiology, estimating disease prevalence, global vaccine issues, infectious disease epidemiology, paediatrics.

INTRODUCTION

Globally, acute lower respiratory tract infections (ALRIs), specifically bronchiolitis [1] are leading causes of childhood morbidity, hospitalization and death. Respiratory syncytial virus (RSV) is one of the most common respiratory viral causes for
childhood ALRI [2–4]. Almost 90% of children are infected by the virus by their second birthday [5, 6]. Studies suggest that the rate of RSV-coded hospitalization in children aged <5 years ranges between 1 and 4/1000 children per year with the rate highest for children aged <6 months [6, 7].

Indigenous children are at increased risk of severe respiratory illness associated with RSV [8]. Data from the USA suggest the rates of RSV hospitalization in American Indian and Alaskan native children are at least 10 times higher than children from the general population. The high rate in these children has been attributed to limited access to health facilities, lack of optimal sanitation facilities and household crowding [9].

Children born preterm [gestational age (GA) <37 weeks] and with chronic lung disease of prematurity/bronchopulmonary dysplasia (BPD) are also at increased risk of being hospitalized with RSV-associated respiratory illness [5]. These infants are also more likely to be hospitalized for a longer period with respiratory infections and are more likely to require specialized care than other children [10].

The Australian perspective

There are few reports of childhood RSV-associated respiratory illness in Australia [11–14]. While these studies provide some insights into the epidemiology of RSV disease in Australia, they do not quantify the population-level burden of disease [12, 15]. Population-based incidence data are necessary to identify specific populations at risk of severe disease in order to prioritize limited health resources for targeted interventions and country-specific requirements for preventive strategies. Population-based estimates also allow comparison of disease burden across different countries. Furthermore, there are limited data regarding the burden of RSV disease in specific sub-populations at high risk including preterm babies and children with BPD in Australia, and no data on Indigenous children despite these children being at an elevated risk [16]. New South Wales (NSW) is the most densely populated state of the country with almost 50% of the country’s Indigenous population living in the state [17].

The aim of this study was to provide updated population-based rates of RSV-associated severe childhood illness in children aged <5 years living in NSW. A comprehensive population-based retrospective analyses of linked administrative datasets was used to achieve this aim.

METHOD

Ethics approval

The project was approved by the NSW Population and Health Service Research Ethics Committee (HREC/09/ CIPHS/33; 2009/05/155) and the Aboriginal Health and Medical Research Council Ethics Committee (726/10).

Study population and follow-up

The study population comprised all children who were born in and resided at birth in NSW between 2001 and 2010. Each child was followed from birth until the end of the study period (31 December 2010) or until the child reached the age of 5 years or died, whichever was earlier.

Data sources

**NSW Perinatal Data Collection (PDC)**

The PDC records all births that are registered in NSW and contains information on mothers and babies comprising birth outcomes such as date of birth, sex of the baby, birth weight, GA and perinatal deaths of babies. The PDC also contains demographic information relating to postcode and state of residence at birth and Indigenous status of the mothers. This dataset was the primary dataset to define the birth cohort for this study.

**Admitted Patient Data Collection (APDC)**

The APDC contains information regarding all separations (discharges, transfers, deaths) following admission to all public and private hospitals of NSW. The data includes age at hospitalization, primary cause of hospitalization, the length of stay, transfer, discharge status, mode of separation, and the cost weight for each hospitalization. The APDC provided the information regarding all respiratory hospitalizations in the study birth cohort.

**Neonatal Intensive Care Units’ (NICUs) data collection**

The NICUs data collection contains information on children (and their mothers) who meet the registration criteria and are admitted to one of the nine NICUs in NSW. This database was used to identify all children with BPD and preterm (GA ≤ 31 weeks requiring admission in one of the NICUs) children in the study cohort.
Virological surveillance data

The Eastern Sydney Laboratory Surveillance Programme conducted by the public health unit of the South Eastern Sydney Local Health District receives a weekly count of RSV detections across all age groups from three pathology laboratories with wide catchment in NSW [18]. This sentinel surveillance data is broadly representative of NSW and was used to determine the trend of RSV-associated respiratory illness transmitted in the community.

Data linkage

The Centre for Health Record Linkage (CHeReL) is the agency responsible for linking of NSW government health databases (www.cherel.org.au) to each other for the purpose of research. CHeReL follows best practice and applies probabilistic linkage [19] to combine personal information in the PDC, APDC and NICUs records to produce a person-based dataset using the NSW PDC as the primary dataset to which all other datasets are linked. Each child is assigned a patient project number (PPN) and this was attached to the records in each source database. All other personal identifiers were removed from each of the datasets and the de-identified datasets with the unique identifier key were provided to the study investigators. One of the study investigators (N.H.) combined records of the same child in the three datasets using the unique identifier key and undertook data cleansing. As the PDC was the master dataset, any records for children in the APDC and NICUs datasets that did not match a PDC record were excluded from the linked data. Infants born outside of NSW were thus excluded from our birth cohort. There were 111 PDC records identified through the linkage as duplicates that were also excluded.

High-risk children

The cohort children were divided into four high-risk groups: children born to Indigenous mothers; children with BPD; preterm children without BPD; and term children born with low birthweight.

(1) Indigenous children. Children of mothers whose ethnicity was recorded as Aboriginal or Torres Strait Islander in PDC, APDC or NICUs datasets were considered to be Indigenous. This did not include Indigenous children who have an Indigenous father and a non-Indigenous mother. Indigenous children were further divided into two groups: Indigenous children with BPD, born preterm or born with low birthweight were classified as Indigenous high-risk children; all other Indigenous children were classified as Indigenous standard-risk children.

(2) Children with BPD. Non-Indigenous children who were born alive at GA ≤ 32 weeks and required oxygen and/or any type of respiratory support on the day they reached 36 weeks GA were classified as children with BPD [20].

(3) Preterm children. We categorized all non-Indigenous babies born with GA <37 weeks into three categories [21]: 32–36 weeks GA, 28–31 weeks GA and <28 weeks GA. None of these children were diagnosed with BPD.

(4) Term children with low birthweight. Non-Indigenous babies born at GA ≥ 37 weeks but with birth weight <2500 g.

Outcome definitions

ALRI and RSV-coded hospitalizations. The International Classification of Diseases, 10th edition (ICD-10), primary diagnostic codes associated ALRI and RSV infection were used to identify all ALRI and RSV-coded hospitalizations from APDC. Primary diagnostic codes listed as whooping cough (A37), pneumonia (J12–J18), bronchiolitis (J21), influenza (J10–J11), unspecified ALRI (J22) and bronchitis (J20) were identified as hospitalization associated with ALRIs. All primary diagnostic codes associated with RSV pneumonia (J12-1), acute RSV bronchitis (J20-5) and acute RSV bronchiolitis (J21-0) and acute bronchiolitis (J21) during the RSV season (April–September) were considered to be hospitalization associated with RSV infection. However all the bronchiolitis cases diagnosed within the RSV season were coded as RSV bronchiolitis in our dataset. Only the primary diagnostic codes were analysed as the primary codes represent the principal diagnosis for which a patient receives admitted care. Secondary codes may represent more severe conditions that occurred during the visit and thus were not included in the analyses to limit inclusion of nosocomial RSV infection. We excluded hospitalizations that occurred within 10 days of neonatal life as these hospitalizations were most likely associated with birth or perinatal complications.

Cost analysis

The NSW Cost of Care Standards 2009/2010 [22] were used to estimate the inpatient hospital costs associated RSV infection. These standards are based on output-based activity-based hospital costs and are used for
NSW funding formulas for hospitals. Acute admitted and newborn costs are primarily derived from the 2006/2007 NSW Hospital Cost Data Collection which captured costs on 1.2 million episodes over 83 NSW hospitals. The standards specify standard costs and cost weights based on the Australian Refined Diagnosis Related Group Version (AR-DRG) for the acute admitted hospital services. The cost weights provide a measure of resource consumption relative to a reference value representing the average inpatient hospital admission in a given year. A cost weight of 1 represents the average cost hospital admission in NSW. At discharge, each episode of acute hospital care is assigned an AR-DRG and associated cost weight which represents its relative resource consumption relative to the reference value. For example, a cost weight of 1.89 means that the admission for a particular class of patients is 89% more costly on average than the average cost.

To estimate hospital costs for RSV admissions, we assigned the weighted ‘total standard NSW public hospital cost’ to the cost weights assigned to each episode of acute hospital care in the APDC using the NSW Costs of Care Standards 2009/2010 [22]. The average costs for acute admitted care (including emergency department and ICU costs) was 4280 AUD for 2009/2010. The average cost assigned to each cost weight was adjusted to 2009/2010 AUD using the deflectors specified in the NSW Costs of Care Standards 2009/2010 which was 4.61% for 2003/2004, 2002/2003 and 2001/2002, 2.90% for 2004/2005, 3.20% for 2005/2006, 3.41% for 2007/2008, 3.55% for 2008/2009 and 3.38% for 2009/2010. For hospitalizations that resulted in transfer to other facilities, the cost was equivalent to the sum of total cost incurred at each of facility.

The AR-DRG classification system accounts for the major part of the variability within a specific AR-DRG. However, the hospital cost data in NSW suggest that there is an additional 10% cost typically incurred by Indigenous patients. Thus in line with the NSW Cost of Care Standards 2009/2010 [22], the costs of episodes of care for Indigenous children were adjusted by a factor of 10% to reflect the additional care requirements and resource consumption [22]. We divided the total cost of all RSV-coded hospitalizations identified over the 10-year period by 10 to estimate the mean annual cost of RSV-coded hospitalizations.

Statistical analysis

We used descriptive statistics to describe the profile of the cohort. Using the dates of respiratory hospitalization from the APDC and the laboratory detection of RSV infections from the virological surveillance data we plotted week and year specific timing of ARI and RSV hospitalizations and RSV circulation in NSW for the study period.

We calculated incidence as the number of new events divided by child-years at risk. A lag of 14 days between two successive respiratory hospitalizations was considered to be a new episode of respiratory hospitalization. Two episodes of respiratory hospitalizations within 48 h and with the same primary ICD-10 AM code were considered continuation of the same illness episode. Moreover, an episode of hospitalization for which the child was transferred to another hospital was considered as continuation of the same illness episode. Children were not considered to be at risk of RSV hospitalization while in the hospital. Person time at risk was calculated by subtracting the number of days spent in hospital from the number of days followed up. Children were divided in to five age groups (0–3 months, 4–6 months, 7–11 months, 12–24 months, 2–<5 years). We used Poisson estimation to calculate 95% confidence intervals (CIs) around incidences. All analyses were performed using Stata release 13 (StataCorp LP, USA).

RESULTS

Profile of the cohort

During 2001–2010, we followed 870 314 children for 3 267 790 person-years (3.8 years/child) and 2295 (0.3%) children died while hospitalized during the follow-up period. A total of 94 082 (11%) children belonged to one of the high-risk groups (Table 1).

Seasonality of RSV illness

Weekly counts of ALRI hospitalization, RSV-coded hospitalization and RSV detection followed similar patterns in NSW over the 10-year period. There was distinct seasonality of ALRI and RSV hospitalizations in NSW. The peak in RSV-coded hospitalizations was between May and August of each year with 81% of the total RSV-coded hospitalizations recorded between these months (Fig. 1).

Incidence of ALRI and RSV hospitalizations

Over the 10-year period there were 68 913 new episodes of ALRI hospitalization. The incidence of ALRI hospitalization (per 1000 child-years) was...
The incidence (per 1000 child-years) of ALRI hospitalization was greater (24·5, 95% CI 24·2–24·7) in male children than female children (17·7, 95% CI 17·5–17·9). The incidences (per 1000 child-years) of ALRI hospitalization for children aged 0–3 months, 4–6 months, 7–11 months, 12–24 months and 2–<5 years, respectively, were 69·9 (95% CI 67·8–70·0), 64·0 (95% CI 63·0–65·2), 25·8 (95% CI 24·8–25·6), 21·7 (95% CI 21·3–22·0) and 7·0 (95% CI 6·8–7·1).

Of 68 913 new episodes of ALRI hospitalization, 16 119 (23%) were coded as RSV (Table 1). In this birth cohort, 35·5% (5720/16 119) of all RSV hospitalizations occurred in children aged 0–3 months, 24·0% (3809/16 119) in children aged 4–6 months, 24·0% (3809/16 119) in children aged 7–11 months, 13·0% (2133/16 119) in children aged 12–24 months and 3·0% (518/16 119) in children aged 2–<5 years.

Cost of illness
The mean cost of each episode of RSV hospitalization in children aged <5 was AUD 6350 (95% CI 6157–6543). For Indigenous children the mean cost for each episode of RSV hospitalization was AUD 9190 (95% CI 8018–10 273). The mean cost associated with each episode of

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of children followed</td>
<td>870 314</td>
</tr>
<tr>
<td>Total person time (years)</td>
<td>3 261 790 (3·8 years/child)</td>
</tr>
<tr>
<td>Male sex of the child (%)</td>
<td>447 942 (51)</td>
</tr>
<tr>
<td>Median birthweight, g (IQR)</td>
<td>3410 (IQR 3070–3745)</td>
</tr>
<tr>
<td>Median GA, weeks (IQR)</td>
<td>39 (38–40)</td>
</tr>
<tr>
<td>Indigenous children (%)</td>
<td>28486 (3)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>3939 (14)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>24 547 (86)</td>
</tr>
<tr>
<td>Children with BPD (%)</td>
<td>823 (0·1)</td>
</tr>
<tr>
<td>Preterm children (%)</td>
<td></td>
</tr>
<tr>
<td>GA 32–36 weeks</td>
<td>45 213 (5)</td>
</tr>
<tr>
<td>GA 28–31 weeks</td>
<td>3779 (0·4)</td>
</tr>
<tr>
<td>GA&lt;28 weeks</td>
<td>1380 (0·2)</td>
</tr>
<tr>
<td>Children born at term with low birthweight (%)</td>
<td>15 224 (2)</td>
</tr>
</tbody>
</table>

All-cause associated acute lower respiratory hospitalizations
Total number of new episodes                          | 68 913
Median age at hospitalization, months (IQR)          | 9 (4–17)
Median length of hospitalization, days (IQR)          | 2 (1–3)

RSV-coded hospitalizations
Total number of new episodes                          | 16 119 (23% of all respiratory hospitalization)
Median age at hospitalization, months (IQR)          | 5 (2–9)
Male sex of the child (%)                             | 9210 (57)
Median length of hospitalization, days (IQR)          | 3 (2–4)

ICD-10 AM coding of RSV-coded hospitalizations
RSV bronchiolitis (%)                                 | 15 393 (95·5)
RSV pneumonia (%)                                     | 643 (4)
RSV bronchitis (%)                                    | 83 (0·5)

BPD, Bronchopulmonary dysplasia; GA, gestational age; IQR, interquartile range; RSV, respiratory syncytial virus.
hospitalization for children with BPD, preterm children
and children born with low birthweight were AUD 12
731 (95% CI 9212–16 251), AUD 9354 (95% CI 8477–
10 233) and AUD 6664 (95% CI 5523–7805), respective-
ly. The mean cost for all other term children was AUD
5649 (95% CI 5475–5823). The mean annual inpatient
hospital cost associated with RSV hospitalization in
NSW was AUD 9 080 000.

DISCUSSION
This is the first study to provide a comprehensive
population-based burden of severe childhood RSV ill-
ness in Australian children including in Indigenous
children. The burden of hospitalization was exception-
ally high in Indigenous children aged <2 years; more
than double the rates in the contemporaneous
non-Indigenous population. The estimated rates in
Australian Indigenous children were comparable to
estimates from American Native children [9, 23].
Respiratory infection has been identified as one of
the major causes for hospitalizations in Indigenous
children [16]. This disproportionate burden of disease
in Indigenous children confirms that this population
continues to be at risk of poorer health outcomes com-
pared to other children [24]. Such high burden of dis-
ease in Indigenous children has been attributed to
poor access to healthcare services, household crowding,
lack of sanitation facilities and indoor exposure to
high levels of smoke [9]. The Indigenous population
of Australia continue to also suffer from social
inequalities [17] highlighting that improving
Indigenous health will require setting priorities for im-
proving socioeconomic indicators of the community.

Our population-based incidence of 4.9/1000 child-
years for RSV hospitalization in children aged <5
years was more than the population-based estimates
of 3–3.5/1000 children in the same age group in the
United States [6, 25]. The incidence was highest in
children aged <6 months, specifically in those aged
<3 months. Although admission criteria and case
definitions may vary from country to country, other
studies have also demonstrated that the burden
remains highest in children aged <6 months [25–27].
Severe RSV disease in very young children is associ-
ated with chronic morbidity including recurrent
wheezing and asthma [28, 29]. In addition, the average
cost of AUD 6350 per RSV-associated hospitalization
was higher than average cost of AUD 5163 per epi-
sode of paediatric hospitalization for acute care in
NSW [30]. The cost was also higher than the mean
cost of US$3799 (equivalent to AUD 5303) associated
with each childhood bronchiolitis hospitalization in
the United States [31]. These factors make develop-
ment of a RSV vaccine a public health priority in
Australia. Although there are several RSV vaccines
and novel anti-RSV therapies in different phases of
clinical trials [32–34], an effective therapy or vaccine
is yet to be licensed. When a vaccine becomes avail-
able, a potential strategy for vaccination may be pas-
sive immunity through maternal immunization for
children aged <6 months and active immunization
for children aged 6–12 months [35].
Table 2. Incidences of RSV hospitalization in children aged <5 years in NSW, 2001–2010

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Number of RSV-coded hospitalizations</th>
<th>Person-years</th>
<th>IR/1000 child-years (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0–3 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous children</td>
<td>392</td>
<td>6793</td>
<td>58·0 (49·5–60·5)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>105</td>
<td>833</td>
<td>126·0 (103·0–152·5)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>287</td>
<td>5960</td>
<td>48·0 (42·7–54·0)</td>
</tr>
<tr>
<td>Children with BPD</td>
<td>3</td>
<td>13</td>
<td>239·0 (47·5–674·4)</td>
</tr>
<tr>
<td>Children with GA 32–36 weeks</td>
<td>539</td>
<td>9200</td>
<td>58·5 (53·7–63·7)</td>
</tr>
<tr>
<td>Children with GA 29–31 weeks</td>
<td>62</td>
<td>1052</td>
<td>173 (133–175·5)</td>
</tr>
<tr>
<td>Children with GA ≤28 weeks</td>
<td>0</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Term children with low birthweight</td>
<td>145</td>
<td>3402</td>
<td>42·6 (36·0–50·0)</td>
</tr>
<tr>
<td>All other term healthy children</td>
<td>4579</td>
<td>178 525</td>
<td>25·6 (23·9–25·3)</td>
</tr>
<tr>
<td><strong>4–6 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous children</td>
<td>348</td>
<td>6478</td>
<td>53·7 (48·2–59·6)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>80</td>
<td>837</td>
<td>95·5 (75·7–119·0)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>268</td>
<td>5640</td>
<td>47·5 (42·0–53·5)</td>
</tr>
<tr>
<td>Children with BPD</td>
<td>38</td>
<td>138</td>
<td>275·0 (194·8–378·0)</td>
</tr>
<tr>
<td>Children with GA 32–36 weeks</td>
<td>367</td>
<td>9106</td>
<td>40·0 (36·2–44·6)</td>
</tr>
<tr>
<td>Children with GA 28–31 weeks</td>
<td>89</td>
<td>638</td>
<td>139·4 (112·0–171·6)</td>
</tr>
<tr>
<td>Children with GA&lt;28 weeks</td>
<td>27</td>
<td>132</td>
<td>205·0 (134·7–297·6)</td>
</tr>
<tr>
<td>Term children with low birthweight</td>
<td>92</td>
<td>3275</td>
<td>28·0 (22·6–34·5)</td>
</tr>
<tr>
<td>All other term healthy children</td>
<td>2869</td>
<td>171 202</td>
<td>16·7 (16·2–17·4)</td>
</tr>
<tr>
<td><strong>7–11 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous children</td>
<td>268</td>
<td>27 178</td>
<td>9·8 (8·7–11·1)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>69</td>
<td>3856</td>
<td>17·8 (14·0–22·6)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>199</td>
<td>23 322</td>
<td>8·5 (7·4–9·8)</td>
</tr>
<tr>
<td>Children with BPD</td>
<td>71</td>
<td>733</td>
<td>96·8 (75·6–122·2)</td>
</tr>
<tr>
<td>Children with GA 32–36 weeks</td>
<td>378</td>
<td>36 663</td>
<td>10·3 (9·3–11·4)</td>
</tr>
<tr>
<td>Children with GA 28–31 weeks</td>
<td>88</td>
<td>3 269</td>
<td>27·0 (21·5–33·0)</td>
</tr>
<tr>
<td>Children with GA&lt;28 weeks</td>
<td>34</td>
<td>631</td>
<td>53·8 (37·3–75·2)</td>
</tr>
<tr>
<td>Term children with low birthweight</td>
<td>79</td>
<td>12 253</td>
<td>6·4 (5·0–8·0)</td>
</tr>
<tr>
<td>All other term healthy children</td>
<td>289</td>
<td>617 877</td>
<td>4·7 (4·5–4·8)</td>
</tr>
<tr>
<td><strong>12–24 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous children</td>
<td>114</td>
<td>22 288</td>
<td>5·0 (4·2–6·0)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>38</td>
<td>3036</td>
<td>12·5 (8·8–17·2)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>76</td>
<td>19 251</td>
<td>4·0 (3·0–5·0)</td>
</tr>
<tr>
<td>Children with BPD</td>
<td>69</td>
<td>712</td>
<td>96·8 (75·4–122·6)</td>
</tr>
<tr>
<td>Children with GA 32–36 weeks</td>
<td>210</td>
<td>31 302</td>
<td>6·7 (5·8–7·7)</td>
</tr>
<tr>
<td>Children with GA 28–31 weeks</td>
<td>31</td>
<td>2414</td>
<td>12·8 (8·7–18·2)</td>
</tr>
<tr>
<td>Children with GA&lt;28 weeks</td>
<td>14</td>
<td>471</td>
<td>29·7 (16·2–49·8)</td>
</tr>
<tr>
<td>Term children with low birthweight</td>
<td>52</td>
<td>11 403</td>
<td>4·5 (3·4–5·0)</td>
</tr>
<tr>
<td>All other term healthy children</td>
<td>1643</td>
<td>583 872</td>
<td>2·8 (2·7–2·9)</td>
</tr>
<tr>
<td><strong>2–&lt;5 years</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous children</td>
<td>16</td>
<td>44 603</td>
<td>0·35 (0·2–0·6)</td>
</tr>
<tr>
<td>High-risk children</td>
<td>4</td>
<td>5614</td>
<td>0·7 (0·02–2·0)</td>
</tr>
<tr>
<td>Healthy children</td>
<td>12</td>
<td>38 988</td>
<td>0·3 (0·2–0·5)</td>
</tr>
<tr>
<td>Children with BPD</td>
<td>21</td>
<td>893</td>
<td>23·5 (14·5–36·0)</td>
</tr>
<tr>
<td>Children with GA 32–36 weeks</td>
<td>54</td>
<td>66 076</td>
<td>0·8 (0·6–1·0)</td>
</tr>
<tr>
<td>Children with GA 28–31 weeks</td>
<td>17</td>
<td>3986</td>
<td>4·2 (0·8–12·0)</td>
</tr>
<tr>
<td>Children with GA&lt;28 weeks</td>
<td>3</td>
<td>719</td>
<td>0·5 (0·01–1)</td>
</tr>
<tr>
<td>Term children with low birthweight</td>
<td>10</td>
<td>41 299</td>
<td>0·4 (0·2–0·7)</td>
</tr>
<tr>
<td>All other term healthy children</td>
<td>385</td>
<td>1 378 996</td>
<td>0·27 (0·25–0·31)</td>
</tr>
</tbody>
</table>

BPD, Bronchopulmonary dysplasia; CI, confidence interval; GA, gestational age; IR, incidence rate; RSV, respiratory syncytial virus.
Similar to other studies, our findings also suggest that RSV-associated hospitalization was highest for children with BPD [36, 37]. While rates of hospitalization for other children at high risk decreased beyond age 2 years, it continued to be high for children with BPD. Preterm children in this cohort also had very high rates of hospitalization. Palivizumab, a monoclonal antibody, can significantly reduce hospitalizations in high-risk infants [38, 39]. While many developed countries use palivizumab for preventing RSV hospitalization in high-risk target groups and have demonstrated its effectiveness [38, 39], prophylactic use of palivizumab remains limited in Australia. In addition there is no standard guideline for its administration. Further well-designed research evaluating the effectiveness and cost-effectiveness of palivizumab in high-risk children especially the Indigenous or preterm infants with or without BPD, may help standardize policy guidelines for lowering the disease burden.

Our study has several limitations. First, we had the data linked until 2010. Linkage of multiple datasets is a time-intensive process and this was the most updated linked data we had access to. There has been no change in treatment of RSV respiratory disease in Australia and our data suggest that number of RSV-coded hospitalizations has remained more or less constant over the 10-year period. Our study has demonstrated that publicly available linked administrative data can be effectively used to quantify disease burden in a population. There may have been missing or incorrect links which is inherent to studies based on large linked datasets. However, CHeReL routinely performs sensitivity analysis for the quality control of the linkage done by them. For our particular study the false-positive rate, i.e. a child in PDC being wrongly linked to an observation in any other dataset was 0-3%. The estimated rates were based on RSV-coded hospitalization which included confirmed and probable RSV hospitalizations and may have resulted in misclassification as testing for RSV is not routine in the clinical setting in NSW. All the RSV-coded hospitalizations were recorded within the RSV season and the RSV-coded hospitalizations and laboratory-confirmed RSV detection rate followed a similar trend suggesting the validity of our estimates. Although RSV is known to be associated with asthma exacerbation and wheeze in children [28], we did not include such hospitalizations. This may have led to underestimation of the burden of RSV; however, we were interested in hospitalizations where RSV was the primary diagnosis for admitted care. We only estimated the rates of RSV hospitalization and there may be significant burden on healthcare services associated with mild RSV illness. However, the aim of the study was to estimate the burden of severe RSV illness so that that data can inform policy decisions regarding prioritizing RSV-specific interventions for specific groups of high-risk children. Although RSV-associated deaths are infrequent [40], we did not have access to the cause-of-death database which limited estimation of RSV-associated mortality rates in this cohort.

The study findings have several important policy implications. The findings confirm that RSV is a major cause of childhood hospitalization, particularly for children aged <3 months in Australia. The burden continues to be highest for Indigenous children and children with BPD and born preterm. However, the high-risk children only accounted for 11% of the study cohort and 23% of all RSV hospitalizations. Most of the disease burden was in otherwise healthy children highlighting the unmet need for an effective vaccine or therapy.

ACKNOWLEDGEMENTS

The authors are grateful to Respiratory Department of Sydney Children’s Hospital, Randwick and Virology Research Laboratory of Prince of Wales Hospital, Randwick for their cooperation. The authors thank the Directors, the NICUs members and the audit officers of all tertiary units in supporting this collaborative study: NICUc, Dr Jennifer Bowen (Chairperson), Barbara Bajuk (Coordinator), Sara Sedgley (Research Officer); Canberra Hospital, Dr Hazel Carlisle (Director), Prof. Alison Kent, Judith Smith; John Hunter Children’s Hospital, Dr Paul Craven (Director), Lynne Cruden, Alissa Argomand; Royal Prince Alfred Hospital, Ingrid Rieger (Director), Dr Girvan Malcolm, Tracey Lutz (Clinical Director), Shelley Reid; Liverpool Hospital, Dr Jacqueline Stack (Director), Dr Ian Callander, Kathryn Medlin, Kaye Marcin; Nepean Hospital, Dr Vijay Shingde, Mee Fong Chin, Kerrie Bonzer; The Children’s Hospital at Westmead, Prof. Nadia Badawi (Director), Dr Robert Halliday, Caroline Karskens; Royal North Shore Hospital, Dr Mary Paradisis (Director), A/Prof. Martin Kluckow, Claire Jacobs; Sydney Children’s Hospital, Dr Andrew Numa (Director), Dr Gary Williams, Janelle Young; Westmead Hospital, Dr Melissa Luig (Director), Jane Baird; and Royal Hospital for Women, A/Prof.
Kei Lui (Director), Dr Ju-Lee Oei, Diane Cameron. We also thank the babies and their families, the nursing and midwifery, obstetric and medical records staff of the obstetric and children’s hospitals in NSW and the ACT.

DECLARATION OF INTEREST

None.

REFERENCES